Abivax Socit Anonyme Stock Fundamentals
AAVXF Stock | USD 11.05 0.00 0.00% |
ABIVAX Socit Anonyme fundamentals help investors to digest information that contributes to ABIVAX Société's financial success or failures. It also enables traders to predict the movement of ABIVAX Pink Sheet. The fundamental analysis module provides a way to measure ABIVAX Société's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABIVAX Société pink sheet.
ABIVAX |
ABIVAX Socit Anonyme Company Shares Outstanding Analysis
ABIVAX Société's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current ABIVAX Société Shares Outstanding | 22.3 M |
Most of ABIVAX Société's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ABIVAX Socit Anonyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, ABIVAX Socit Anonyme has 22.3 M of shares currently outstending. This is 87.65% lower than that of the Healthcare sector and 79.13% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 96.1% higher than that of the company.
ABIVAX Socit Anonyme Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ABIVAX Société's current stock value. Our valuation model uses many indicators to compare ABIVAX Société value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ABIVAX Société competition to find correlations between indicators driving ABIVAX Société's intrinsic value. More Info.ABIVAX Socit Anonyme is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ABIVAX Société's earnings, one of the primary drivers of an investment's value.ABIVAX Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ABIVAX Société's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ABIVAX Société could also be used in its relative valuation, which is a method of valuing ABIVAX Société by comparing valuation metrics of similar companies.ABIVAX Socit is currently under evaluation in shares outstanding category among its peers.
ABIVAX Fundamentals
Return On Equity | -12.86 | |||
Return On Asset | -0.44 | |||
Operating Margin | 4.66 % | |||
Current Valuation | 165.28 M | |||
Shares Outstanding | 22.3 M | |||
Shares Owned By Insiders | 4.67 % | |||
Shares Owned By Institutions | 57.27 % | |||
Price To Earning | (7.88) X | |||
Price To Book | 27.57 X | |||
Price To Sales | 20.65 X | |||
Revenue | 37 K | |||
Gross Profit | (45.52 M) | |||
EBITDA | (42.25 M) | |||
Net Income | (41.36 M) | |||
Cash And Equivalents | 26.57 M | |||
Cash Per Share | 1.58 X | |||
Total Debt | 53.45 M | |||
Debt To Equity | 8.03 % | |||
Current Ratio | 2.03 X | |||
Book Value Per Share | 0.36 X | |||
Cash Flow From Operations | (45.66 M) | |||
Earnings Per Share | (2.59) X | |||
Number Of Employees | 24 | |||
Beta | 1.26 | |||
Market Capitalization | 165.36 M | |||
Total Asset | 110.36 M | |||
Z Score | 1.8 | |||
Net Asset | 110.36 M |
About ABIVAX Société Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABIVAX Socit Anonyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABIVAX Société using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABIVAX Socit Anonyme based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ABIVAX Socit Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. The company was incorporated in 2013 and is headquartered in Paris, France. Abivax Sa is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in ABIVAX Pink Sheet
ABIVAX Société financial ratios help investors to determine whether ABIVAX Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABIVAX with respect to the benefits of owning ABIVAX Société security.